Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
To describe imaging findings in human cancer with the new hypoxia tracer 124IAZGP and PET/CT
at least once at approximately 6 hours and/or 24 hours after radiotracer administration.
No
Heiko Schöder, MD
Principal Investigator
Memorial Sloan-Kettering Cancer Center
United States: Food and Drug Administration
05-023
NCT00588276
June 2005
June 2012
Name | Location |
---|---|
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |